On a crisp October day, the CEO of Moderna, of COVID-vaccine fame, is sitting in his glass-walled office in the company’s headquarters in Cambridge, Mass., weeks before encouraging results from the company’s first mRNA cancer vaccine would become public.
asserted
results → sit → vaccine
He’s recounting the biotech’s rocky road turning an unproven, scientifically dismissed approach—using messenger RNA, or mRNA, the genetic code that instructs cells to make proteins—into a platform for producing new categories of medicines.
asserted
that → recount → medicines
Fifteen years ago, Bancel had his doubts.
asserted
Bancel → have → doubts
At the time, there were no approved mRNA-based products on the market, and most scientists would have agreed that mRNA was too unstable to form the basis of a new class of medical treatments.
asserted
mRNA → be → treatments
In fact, the entire biotech industry had bet—successfully—on manipulating another, more reliable genetic material: DNA.
asserted
industry → bet → material
“It was crazy to think of using mRNA as a drug,” Bancel reflects.
asserted
Bancel → think → drug
But that was before a fateful meeting forced him to look at the genetic material in a different way, and realize that with the right manipulation, mRNA provided a way to make drugs that were never possible with existing strategies.
asserted
that → force → strategies
Now, he believes that nearly any protein drug made today with existing, recombinant DNA technology can also be made using mRNA.
asserted
drug → believe → mRNA
The company’s goal isn’t to follow the usual road map and make one type of drug for one disease at a time, but to build a new platform from which a variety of different treatments can be developed in a plug-and-play scenario—similar to how the computer-technology industry is built on the foundational hardware and operating systems around which a whole universe of software has blossomed.
asserted
universe → follow → software
“mRNA is the information molecule, so if you find the way to safely and effectively get it into the right cells, you can unlock a lot of medicines to help people’s suffering,” says Bancel.
asserted
Bancel → find → suffering
Moderna’s mRNA COVID vaccine saved an estimated 2 million lives globally—while earning the company $46 billion—from 2021 to 2024.
asserted
vaccine → save → 2024
This fall, people are getting its newly approved mRNA flu shot, the first of its kind.
asserted
people → get → kind
And in October, Moderna announced with Merck that their mRNA approach also worked to stimulate the immune system to fight cancer—creating a therapeutic vaccine, rather than a preventative one.
asserted
approach → announce → one
Intismeran, combined with one of Merck’s drugs, successfully kept melanoma from recurring in a group of patients with mid- to late-stage disease.
asserted
Intismeran → combine → disease
By the end of the year, Bancel says, he expects to unveil similarly encouraging results from Moderna’s first mRNA therapy for a rare disease.
asserted
he → say → disease
In just over a decade, mRNA has gone from molecular misfit to biomedical golden child, in no small part because of Bancel’s efforts at Moderna to prove the naysayers wrong.
asserted
naysayers → go → Moderna
“At the beginning, it was either zero drugs, or we find a way to climb this mRNA mountain and make a lot of drugs,” says Bancel.
asserted
Bancel → find → drugs
Consider vaccines, where mRNA is quickly becoming the preferred technology for its speed.
asserted
mRNA → consider → speed
Scientists at Moderna can create a vaccine against any pathogen within six to eight weeks—far faster than it takes to then conduct the human studies required by regulatory agencies to establish a therapy’s safety and efficacy.
asserted
it → create → safety
Cancer researchers hope to harness that speed with customized mRNA vaccines like intismeran.
asserted
researchers → hope → intismeran
That’s what Bancel saw in mRNA more than a decade ago: an untapped vein of therapeutic ore.
asserted
Bancel → ’ → ore
With mRNA, once it’s properly instructed to make the right proteins to fight a virus, fix a genetic disease, or tackle a tumor, the human body becomes its own treatment factory.
asserted
body → instruct → tumor
Over a series of interviews with TIME spanning several years, Bancel unveiled the story of how a startup betting on an untested technology came to sit at the same table as decades-old pharmaceutical giants, and now holds the key to a transformative platform that could redesign treatments in three critical areas: infectious diseases, rare diseases, and cancer.
uncertain
that → span → areas
Born in Marseilles, Bancel grew up with a strong interest in math and science, fueled in part by his father, an engineer who was always fixing things around the house.
asserted
who → bear → house
“We used to sail in the summer, and one summer my brother and father and I sailed from Marseilles to Mallorca—a two-day trip—and the engine broke in the middle of the water in the middle of the night,” he says.
asserted
he → use → night
“I remember we were holding the flashlight above him, and he was fixing the engine by himself.”
asserted
he → remember → himself
Bancel was pursuing a degree in chemical engineering at Ecole Centrale Paris when, on a whim, he took a genetics class at the university next door and “fell in love with genetics,” he says.
asserted
he → pursue → genetics
He went on to earn a master’s in chemical engineering at the University of Minnesota and an M.B.A. from Harvard Business School before working at Eli Lilly in Indianapolis for six years, mostly in manufacturing.
asserted
He → go → manufacturing
In 2006, he became CEO of the French diagnostics company bioMérieux.
asserted
he → become → company
He was working in the company’s Boston office in 2011 when he got a call from his friend Noubar Afeyan, founder of Flagship Pioneering, a venture-capital firm and health-startup incubator.
asserted
he → work → Pioneering
Bancel served on the boards of several of Afeyan’s startups and had already turned down multiple offers to lead some of the new companies.
asserted
Bancel → serve → companies
But Afeyan thought he finally had one that might entice his friend.
uncertain
that → think → friend
Afeyan had been approached by a trio of scientists with the idea for a company to develop new treatments from mRNA.
asserted
Afeyan → approach → mRNA
He showed Bancel data from a handful of mice that had been injected with human mRNA to make a human protein.
asserted
that → show → protein
“I’m like, ‘This is impossible, because everything we learned in biology is that if you inject mRNA, you create an immune response,’” says Bancel.
asserted
Bancel → ’m → response
But what if it worked?
asserted
it → work → ?
Afeyan persisted.
asserted
Afeyan → persist → ?
What would it mean?
asserted
it → mean → What
“I said, if it works, you’re going to be able to make hundreds, maybe thousands of medicines that you cannot using [current] biotech technology,” says Bancel.
asserted
Bancel → say → technology
Up to that point, the biotech industry was focused on manipulating DNA and making products to work on molecules that cells secreted—all in cell cultures using bacteria or viruses that were genetically engineered to produce the molecule in question.
asserted
that → focus → question
…and 153 more, not listed.